BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$81.03 USD
-0.69 (-0.84%)
Updated May 10, 2024 04:00 PM ET
After-Market: $81.01 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
BMRN 81.03 -0.69(-0.84%)
Will BMRN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Other News for BMRN
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
The 3 Best Biotech Stocks to Buy in May 2024
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
An Update On Ascendis Pharma's Path To Profitability
BioMarin touts new data on Voxzogo for additional indications